These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 24846035)

  • 1. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
    McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS
    JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
    Stroup TS; Bareis NA; Rosenheck RA; Swartz MS; McEvoy JP
    J Clin Psychiatry; 2018 Nov; 80(1):. PubMed ID: 30549494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
    Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
    J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
    Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
    Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
    Covell NH; McEvoy JP; Schooler NR; Stroup TS; Jackson CT; Rojas IA; Essock SM;
    J Clin Psychiatry; 2012 May; 73(5):669-75. PubMed ID: 22480442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
    Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D
    Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.
    Sliwa JK; Fu DJ; Bossie CA; Turkoz I; Alphs L
    BMC Psychiatry; 2014 Feb; 14():52. PubMed ID: 24559194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
    Alphs L; Bossie C; Mao L; Lee E; Starr HL
    Early Interv Psychiatry; 2018 Feb; 12(1):55-65. PubMed ID: 26403322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
    Sajatovic M; Levin J; Ramirez LF; Hahn DY; Tatsuoka C; Bialko CS; Cassidy KA; Fuentes-Casiano E; Williams TD
    J Clin Psychiatry; 2013 Dec; 74(12):1249-55. PubMed ID: 24434094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.